Pharmaceutical company Gilead Sciences has come under mounting pressure after refusing to sell its breakthrough HIV prevention drug, lenacapavir, directly to Médecins Sans Frontières (MSF), despite repeated requests. In an open letter, the group renewed its repeated requests to California-based Gilead to sell the drug, saying the company is blocking lenacapavir’s rollout. MSF said it had sought to purchase…
Blocking humanitarian organizations from accessing a medical breakthrough puts vulnerable people across the world in danger. In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company…
Geneva/Paris — This World Tuberculosis (TB) Day, Médecins Sans Frontières (MSF) urges governments and international donors to bring children to the heart of the global TB response, and commit to investing in the diagnosis, treatment, and prevention of TB in children. No child should suffer or die from a disease that is both preventable and…
Global efforts to fight three of the world’s most harmful and widespread infectious diseases—AIDS, tuberculosis and malaria—are now under threat due to dramatic cuts in global health financing, warns Doctors Without Borders (MSF). In January, the United States—previously the largest funder of global health programs—announced a suspension and review of all international aid. Since then,…
